Cohen & Steers Global Realty Majors ETF (GRI): Price and Financial Metrics ETF

Cohen & Steers Global Realty Majors ETF (GRI): $2.66

0.15 (+5.98%)

POWR Rating

Component Grades

Buy & Hold

F

Peer

D

Add GRI to Watchlist
Sign Up

Category: Global Real Estate ETFs

Category

C

Ranked

#9 of 12

in category

GRI Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market

Current price $2.66 52-week high $561.47
Prev. close $2.51 52-week low $2.46
Day low $2.46 Volume 290,600
Day high $3.00 Avg. volume 53,489
50-day MA $4.90 Dividend yield N/A
200-day MA $46.27

GRI Stock Price Chart Interactive Chart >


Cohen & Steers Global Realty Majors ETF (GRI) ETF Bio


The investment objective of the Cohen & Steers Global Realty Majors ETF seeks to benefit from the potentially substantial and growing long-term income streams and diversification benefits that global real estate securities and REIT structures may provide.

GRI ETF Info

Issuer
Expense Ratio %
Asset Class
Sector Global Real Estate ETFs
Assets Under Management (AUM) N/A
Net Asset Value (NAV) $0.00
Options? No
Total Holdings N/A

GRI Top Holdings

Symbol Company % of Total

Latest GRI News From Around the Web

Below are the latest news stories about GRI BIO INC that investors may wish to consider to help them evaluate GRI as an investment opportunity.

GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment

GRI Bio CEO Marc Hertz joined Steve Darling from Proactive to share news the company has begun patient enrollment in a Phase 2a biomarker study focused on evaluating GRI-0621 as a potential treatme...

Yahoo | December 6, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning!

William White on InvestorPlace | December 5, 2023

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival1 LA JOLLA, CA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibroti

Yahoo | December 5, 2023

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited compliance and no impact on survival1 Management discusses IND clearance and what this milestone means in a brief video: here LA JOLLA, CA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a

Yahoo | November 27, 2023

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance and no impact on survival1 GRI-0803 systemic lupus erythematosus (“SLE”) program advancing towards completion of IND-enabling studies with IND filing on track for H1 2024 Annual prevalence estimated to be ~161,0

Yahoo | November 15, 2023

Read More 'GRI' Stories Here

GRI Price Returns

1-mo -50.46%
3-mo -73.87%
6-mo N/A
1-year -99.46%
3-year -99.94%
5-year -99.99%
YTD -92.41%
2023 -95.57%
2022 -85.45%
2021 N/A
2020 0.00%
2019 21.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!